Andreas Jeromin, PhD, has established research programs in translational neuroscience in both industry and biotech for the last 15 years and co-authored more than 100 publications. He has also been elected a member of the Dana Alliance for Brain Initiatives. Andreas Jeromin has led biomarker qualification programs in diagnostics and therapeutics in acute neurological injury and neurodegeneration. This included several drug development programs from POC to a NINDS-supported phase III trial (Protect III). He also supports as member of the SABs or steering committee, several biomarker qualification efforts such as ADNI, the Coalition against Major Diseases (CAMD) directed by the Critical Path Institute (C-PATH), the Alzheimer's Association CSF QC and biomarker assay standardization initiatives in other CNS disorders, including MS (Accelerated Cure, ALS and PD. He is the founder and CSO of Atlantic Biomarkers, LLC, and joined Quanterix, Inc. as scientific and medical advisor in 2014.